Exosome Diagnostics, Inc.

The Brigham and Women's Hospital, Inc.

Robert Kitchen

Johan Karl Olov Skog

Wei Yu

Johan Skog

Vasisht Tadigotla

Dalin Chan

James Hurley

Christine Coticchia

Michael Valentino

Sudipto Chakrabortty

Mia Sher

Jamil Azzi

Dominik Grimm

Elena Castellanos-Rizaldos

Georg Stoll

Erez Eitan

Seth Yu

Douglas Roberts

Olubode A Ogunlusi

The present disclosure relates to compositions, methods and kits for the isolation of extracellular vesicles. The compositions, methods and kits can comprise a high-density liquid reagent that facilitates the sequestration of extracellular vesicles bound to magnetic beads.

Compositions, methods, and kits for the isolation of extracellular vesicles

The present disclosure relates to methods for detecting and treating bladder cancer in a subject using the gene expression level measurements from exosomes derived from the subject.

Methods for developing urine biomarkers and for detecting bladder cancer

The invention relates generally to a process for isolating subpopulations of EVs to identify biomarkers useful identifying, determining the progression of, and/or prognosing a disease, including a neurological disease. More particularly, the present invention relates to detection technology of various exosomal biomarkers including proteins, protein modifications, sugars, RNA, DNA, lipids, and metabolites, and combinations thereof.

Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles

The invention relates generally to the use of microvesicle biomarkers such as nucleic acids, including nucleic acid signatures, and/or proteins for assessing a kidney transplant rejection in a patient. The invention further relates to assessing, and/or to monitoring kidney transplant rejection in patients who have received a renal transplant.

Methods of detecting renal transplant rejection using microvesicle nucleic acid biomarkers

The invention provides a series of steps that prepare nucleic acids (RNA and/or DNA) isolated from extracellular vesicles for sequencing. This enables a wide diversity of RNAs and/or DNAs, to be efficiently detected. These can then be used to identify various attributes such as gene expression, alternative splicing, and the detection of both somatic and germline mutations including single nucleotide variants (SNV) and structural variations (insertions/deletions, fusions, inversions).

Sequencing and analysis of exosome associated nucleic acids

The present disclosure relates to methods for treating glioblastoma in a subject in need thereof using gene signatures in exosomal RNA derived from the subject. The gene signatures comprise: at least one of FAM229B, ZNF35, CTD-2647L4.4, CABP5, CYP20A1, CEP126, DTX2P1-UPK3BP1-PMS2P11, RP11-507K12.1, KRBA2, CALD1, LRFN1, RP2, SLC2A13, CDKL3, SLC8A3, ANTXR2, TIGD5, AC074289.1 RP11-932O9.7; at least one of tRNA-Lys-CTT-2-2, tRNA-Pro-AGG-2-7, LAMTOR2, RAD51AP1, DENND2A, A1BG, THSD1, CSF1, RP11-332M2.1, ZNF717, ZNF860, ORC6, Clorf50, PSPH, HIST1H4C, CYP2U1, THAP8, TMEM192, NAA20; or at least one of CREBBP, CXCR2 and S100A9. The treatment methods comprise measuring the expression level of at least one of the aforementioned genes in exosomal RNA from a subject and administering to the subject a glioblastoma treatment based on the expression level(s).

Methods of treating glioblastoma in a subject informed by exosomal RNA signatures

Growing community of inventors

Somerville, MA, United States of America

Robert Kitchen